Latest Spinogenix News & Updates
See the latest news and media coverage for Spinogenix. We track all announcements, press releases, and industry mentions in real time, all in one place.
Synaptic regenerative therapeutics for brain disorders
spinogenix.com- Headquarters
- Los Angeles, United States
- Founded year
- 2016
- Company type
- Private company
- Number of employees
- 4–10
Last updated
Latest news about Spinogenix
Company announcements
-
Spinogenix receives FDA Fast Track Designation for tazbentetol in ALS
This enables expedited development following Phase 2a results showing slowed decline in patients. The company continues its Expanded Access Program.
-
Spinogenix presents preclinical results on tazbentetol at ARVO 2026
Data show neuroprotective effects in glaucoma and diabetic retinopathy models, preserving retinal cells and visual function. Quote from CEO Stella Sarraf.
-
Spinogenix founder speaks at symposium
Stella Sarraf shares her journey and Spinogenix's progress in synapse regeneration for ALS, Alzheimer’s, schizophrenia, and Fragile X, with positive trial readouts.
-
Spinogenix announces CLARITY Phase 2b/3 trial
It will evaluate oral SPG601 in male Fragile X patients, assessing EEG biomarkers and cognitive outcomes across dose regimens.
Media coverage
-
Spinogenix Receives U.S. FDA Fast Track Designation for Tazbentetol for the Treatment of ALS
Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering novel therapeutics that have the potential to restore synapses to improve the lives of patients worldwide, today announced...
-
Spinogenix to Present Preclinical Results at ARVO 2026 Demonstrating Neuroprotective Effects of Tazbentetol in Glaucoma and Diabetic Retinopathy Models
Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics designed to restore synapses to improve the lives of patients, will present this week the results...
-
Spinogenix Announces CLARITY: a Phase 2b/3 trial of SPG601 for the Treatment of Fragile X Syndrome
Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics designed to restore synapses to improve the lives of patients, is initiating CLARITY, a Phase 2b/3...
-
FRAXA Backs Upcoming Phase 2B Trial of SPG601 for Fragile X Syndrome • FRAXA Research Foundation - Finding a Cure for Fragile X Syndrome
Research Updates • Spinogenix, Inc.
Track Spinogenix and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Spinogenix competitors & trending companies
Browse news for competitors to Spinogenix and other trending companies.
Raya
Origami Therapeutics
QurAlis
Alzinova
Dunad Therapeutics
AL-S Pharma
Pit
Davis AI
Qutwo
DigiPowerX
Penguin Solutions
Sterling Infrastructure
KIOXIA Corporation
Subquadratic
Tibber
IREN
A24
Hitachi Energy
Ouster
Ormat Technologies
Fabrinet
AOI
WidePoint
Filtronic
Mirum Pharmaceuticals
Capstone Green Energy
AXT
POET Technologies
PurpleFire
Profitable Media
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio